Has Rakesh Patel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,271 in general payments to Rakesh Patel, MD across 179 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rakesh Patel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rakesh Patel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rakesh Patel, MD

Pain Medicine · Hamden, CTNPI 1053355693

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.2% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 32.8% of the total. Reporting peaked in 2019 at $766 and has fallen 96.2% since, to $29 in 2025. That places this record below the midpoint for pain medicine clinicians in CT, where the typical reported total is $2,061.

$2,271in general payments, 2019–2025

Across 179 payments — averaging $12.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$745
Collegium Pharmaceutical, Inc.$332
SPR Therapeutics, Inc$139
Scilex Pharmaceuticals Inc.$137
Novo Nordisk$123
Relievant Medsystems, Inc.$123
plus $672 from 16 others

What the payments were for

Food & beverage$2,18696%
Education$864%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	94	$745
Collegium Pharmaceutical, Inc.	45	$332
SPR Therapeutics, Inc	1	$139
Scilex Pharmaceuticals Inc.	9	$137
Novo Nordisk	1	$123
Relievant Medsystems, Inc.	2	$123
Olympus America Inc.	1	$120
Livanova USA, Inc.	1	$100
Biodelivery Sciences International, Inc.	6	$89
Vertex	2	$46
Tactile Systems Technology Inc	2	$43
Valinor Pharma, LLC	2	$42
Pfizer	2	$34
Cvrx, Inc.	1	$34
Sentynl Therapeutics, Inc.	2	$28
Kaleo, Inc.	2	$25
Boehringer Ingelheim	1	$24
Endo Pharmaceuticals Inc.	1	$24
GRT US Holding, Inc.	1	$20
Nevro Corp.	1	$17
Shionogi Inc	1	$13
Amgen	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,271 in reported general payments places this provider in the 50th percentile of 69 pain medicine providers in Connecticut.

See all pain medicine providers in Connecticut →

Medicare billing

Part B allowed, 2024

$144,370

Medicare patients

301

Services billed

3,964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OxycontinOxycodone Hcl	63	$42,205
Oxycodone Hcl	327	$7,316
Fentanyl	36	$3,732
Morphine Sulfate ErMorphine Sulfate	94	$3,312
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	123	$3,217
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	131	$2,608
Morphine Sulfate	34	$1,869
Gabapentin	118	$1,516
Pregabalin	68	$1,214
Tramadol Hcl	147	$990
Tizanidine Hcl	56	$747
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	12	$561
Hydromorphone Hcl	25	$377
Methocarbamol	32	$325
Baclofen	13	$222

Paid to pharmacies, not to this prescriber.

Other pain medicine in Hamden

Sandeep JoharWaterbury$329K
David GutierrezNew Haven$151K
Brian GrosbergWest Hartford$99K
Ofer WellischStamford$18K
Yili HuangNew Haven$18K
Jared RosenbergGreenwich$12K
Sandhya MehlaWest Hartford$12K
Hans KnoppMiddlebury$11K
Daniel HaddadNew Haven$10K
Rahul AnandFairfield$9K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →